A study introduces a scalable 2D human neuron platform to probe how brain-like rhythms emerge and how specific drugs reshape them, aiding epilepsy and autism research.

The U.S. Food and Drug Administration approved Cobenfy on September 26, 2024, making it the first schizophrenia drug with a ...

AHARA Mushrooms today published the results of the most comprehensive metabolomic analysis ever conducted on a mushroom ...

This review examines the epidemiology, health risks, neurobiological mechanisms, and emerging treatments related to betel nut ...

As an innovative subtype of invasive brain-computer interfaces (BCIs), the Endovascular Brain-Computer Interface (EBCI) enables electrode delivery to target brain regions via endovascular intervention ...

BackgroundAlzheimer's disease (AD) is the most common neurodegenerative disorder, characterized by progressive cognitive decline and memory impairment ...

Neuromuscular blocking agents have been used prior to surgery since their development in the 1940s. While some agents have fallen out of popularity, others were advanced and utilized to facilitate ...

Drug treatments for schizophrenia have barely changed in 70 years, but a mix of chance and ingenuity offers fresh hope ...

New drugs were approved for the oncology field, and for treating ophthalmic, gastrohepatic, hemologic, and metabolic disorders.

The eastern diamondback rattlesnake is considered to be one of the most dangerous animals in the United States, while other ...